Table 2.
Baseline demographic and clinical data of the study population.
| NOA (n = 12) | OA (n = 22) | O (n = 13) | |
|---|---|---|---|
| Age, years | 54.5 (41.5–59.5) | 57.0 (51.0–61.5) | 47.0 (45.5–61.5) |
| Female, n (%) | 10 (83.3) | 18 (81.8) | 11 (84.6) |
| BMI, kg/m2 | 23.2 (22.0–25.0) | 38.0 (35.1–45.0) * | 42.2 (38.4–47.9) * |
| Mild asthma, n (%) | 0 (0) | 4 (18.2) | N/A |
| Moderate asthma, n (%) | 5 (41.7) | 5 (22.7) | N/A |
| Severe asthma, n (%) | 7 (58.3) | 13 (59.1) | N/A |
| FVC, % predicted | 128.0 (112.3–138.5) | 110.5 (94.5–119.3) * | 118.5 (105.5–125.8) |
| FEV1, % predicted | 79.0 (69.8–98.5) | 79.0 (61.5–93.5) | 90.0 (87.0–100.8) |
| FEV1/FVC | 65.5 (57.0–74.8) | 76.0 (66.5–80.5) | 80.5 (75.0–82.8) * |
| Use of ICS §, n (%) | 10 (83.3) | 16 (72.7) | N/A |
| Atopia, n (%) | 8 (66.7) | 9 (40.9) | N/A |
| Serum total IgE, kU/L | 122.0 (42.3–409.0) | 63.7 (14.4–149.0) | 50.0 (17.9–112.5) |
| BEC, % | 4.8 (3.3–6.6) | 3.3 (2.3–4.9) | 2.8 (1.4–3.5) * |
| BEC, cells/µL | 300 (200–500) | 200 (200–400) | 200 (100–300) |
| BEC ≥ 300 cells/µL, n (%) | 8 (66.7) | 7 (31.8) | 3 (23.1) |
Data presented as medians (25th–75th percentile). NOA, non-obese asthmatics; OA, obese asthmatics; O, obese subjects; BEC, blood eosinophil count; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; IgE, immunoglobulin E; N/A, no applicable. * p < 0.05, compared with NOA; Kruskal–Wallis H followed by Dunn’s multiple comparisons test. § For NOA and OA patients who received ICS, the mean ± SD of the ICS dose in budesonide equivalents was 680.0 ± 518.5 and 1356.2 ± 913.7 µg/day, respectively.